Last reviewed · How we verify

Pegasys /RBV — Competitive Intelligence Brief

Pegasys /RBV (Pegasys /RBV) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alfa-2a (pegylated) + nucleoside analog combination. Area: Virology/Hepatology.

phase 3 Interferon alfa-2a (pegylated) + nucleoside analog combination Interferon-alpha receptor; HCV RNA-dependent RNA polymerase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Pegasys /RBV (Pegasys /RBV) — Beijing Kawin Technology Share-Holding Co., Ltd.. Pegasys (peginterferon alfa-2a) is an interferon that activates the immune system to fight viral infections, while ribavirin (RBV) is a nucleoside analog that inhibits viral replication.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pegasys /RBV TARGET Pegasys /RBV Beijing Kawin Technology Share-Holding Co., Ltd. phase 3 Interferon alfa-2a (pegylated) + nucleoside analog combination Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Peg-IFN + RBV Peg-IFN + RBV National Taiwan University Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
C: Peg-interferon alpha-2a & Ribavirin C: Peg-interferon alpha-2a & Ribavirin Kaohsiung Medical University Chung-Ho Memorial Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Peg-interferon alpha 2a and ribavin Peg-interferon alpha 2a and ribavin Hospices Civils de Lyon phase 3 Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alfa-2a (pegylated) + nucleoside analog combination class)

  1. Beijing Kawin Technology Share-Holding Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegasys /RBV — Competitive Intelligence Brief. https://druglandscape.com/ci/pegasys-rbv. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: